secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056294
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma Q1 loss narrows to $15.3M; Phase 2 PYNNACLE trial initiated
----------------------------------------------------------------------

- Net loss $15.3M vs $19.1M YoY; cash $213.1M, expected runway to end of 2026.
- First patient dosed in registrational Phase 2 PYNNACLE trial for rezatapopt (TP53 Y220C/KRAS wild-type).
- Phase 1 ovarian cancer data: 7/15 confirmed partial responses, median duration 7 months.
- R&D expenses $13.2M (down from $15.1M); G&A $5.0M (down from $6.4M).
- Net cash used in operations $16.2M vs $15.0M in Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000095017024056294/0000950170-24-056294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000095017024056294/pmvp-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer